Harriet Kluger

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival
    Aaron J Berger
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer Res 63:8103-7. 2003
  2. ncbi request reprint Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma
    Kyle A Divito
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8773-7. 2004
  3. pmc Drug targets and predictive biomarkers in the management of metastatic melanoma
    Jaykumar Thumar
    Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
    Pharmgenomics Pers Med 5:139-48. 2012
  4. pmc Expression of drug targets in patients treated with sorafenib, Carboplatin and Paclitaxel
    Lucia B Jilaveanu
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America
    PLoS ONE 8:e69748. 2013
  5. doi request reprint MEK targeting in N-RAS mutated metastatic melanoma
    Jaykumar Thumar
    Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, WWW213, New Haven, CT 06520, USA
    Mol Cancer 13:45. 2014
  6. pmc Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
    Fabio Parisi
    Department of Cell Biology, New York University Center for Health Informatics and Bioinformatics, New York University School of Medicine and Cancer Institute, NY 10016, USA
    Breast Cancer Res 12:R66. 2010
  7. ncbi request reprint Studies of NVP-BEZ235 in melanoma
    Joshua A Sznol
    Section of Medical Oncology, 333 Cedar Street, New Haven, Connecticut, 06520, USA
    Curr Cancer Drug Targets 13:165-74. 2013
  8. pmc Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
    Saadia A Aziz
    Department of Medicine and Yale Cancer Center, 333 Cedar St, WWW213, New Haven, CT, 06520, USA
    BMC Clin Pathol 13:3. 2013
  9. pmc Vascularity of primary and metastatic renal cell carcinoma specimens
    Saadia A Aziz
    Department of the School of Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Transl Med 11:15. 2013
  10. pmc Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
    Aymen A Elfiky
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, United States of America
    J Transl Med 9:133. 2011

Research Grants

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival
    Aaron J Berger
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer Res 63:8103-7. 2003
    ..Moreover, our findings suggest that ATF2 might be a useful prognostic marker in early-stage melanoma...
  2. ncbi request reprint Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma
    Kyle A Divito
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8773-7. 2004
    ..These results suggest studies are needed to evaluate the association between quantitative assessment of Bcl-2 expression and response to Bcl-2 targeting therapy toward the goal of improved response rates to these drugs...
  3. pmc Drug targets and predictive biomarkers in the management of metastatic melanoma
    Jaykumar Thumar
    Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
    Pharmgenomics Pers Med 5:139-48. 2012
    ..In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease...
  4. pmc Expression of drug targets in patients treated with sorafenib, Carboplatin and Paclitaxel
    Lucia B Jilaveanu
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America
    PLoS ONE 8:e69748. 2013
    ....
  5. doi request reprint MEK targeting in N-RAS mutated metastatic melanoma
    Jaykumar Thumar
    Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, 333 Cedar Street, WWW213, New Haven, CT 06520, USA
    Mol Cancer 13:45. 2014
    ..Our purpose was to study clinical characteristics of patients with mutations in this pathway and to determine activity of inhibitors of B-RAF and MEK in short term cultures grown from tumors of some of these patients...
  6. pmc Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
    Fabio Parisi
    Department of Cell Biology, New York University Center for Health Informatics and Bioinformatics, New York University School of Medicine and Cancer Institute, NY 10016, USA
    Breast Cancer Res 12:R66. 2010
    ..We generated prognostic models that incorporate protein-based molecular markers and clinico-pathological variables to improve survival prediction...
  7. ncbi request reprint Studies of NVP-BEZ235 in melanoma
    Joshua A Sznol
    Section of Medical Oncology, 333 Cedar Street, New Haven, Connecticut, 06520, USA
    Curr Cancer Drug Targets 13:165-74. 2013
    ..In this review, we discuss targeting different members of this pathway, potential escape mechanisms, classes of specific molecular inhibitors, and development of NVP-BEZ235, a novel dual PI3k/mTOR inhibitor...
  8. pmc Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
    Saadia A Aziz
    Department of Medicine and Yale Cancer Center, 333 Cedar St, WWW213, New Haven, CT, 06520, USA
    BMC Clin Pathol 13:3. 2013
    ..abstract:..
  9. pmc Vascularity of primary and metastatic renal cell carcinoma specimens
    Saadia A Aziz
    Department of the School of Medicine, Yale University School of Medicine, New Haven, CT, USA
    J Transl Med 11:15. 2013
    ..Clinical studies suggest that metastatic sites are more responsive than primary tumors. Our purpose was to characterize microvessel area (MVA) in matched primary and metastatic samples and in samples of different histologies...
  10. pmc Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
    Aymen A Elfiky
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, United States of America
    J Transl Med 9:133. 2011
    ..We characterized expression of p85 and p110α PI3K subunits and mTOR in RCC specimens and assessed pharmacologic co-targeting of these molecules in vitro...
  11. pmc Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
    Jill C Rubinstein
    Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Transl Med 8:67. 2010
    ..Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations...
  12. pmc Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
    Yasmine Nadler
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Breast Cancer Res 10:R35. 2008
    ....
  13. pmc Characterizing disease states from topological properties of transcriptional regulatory networks
    David P Tuck
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    BMC Bioinformatics 7:236. 2006
    ..We analyzed expression datasets from a number of diseased and normal cells, including different types of acute leukemia, and breast cancer with variable clinical outcome...
  14. ncbi request reprint cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Lab Invest 84:320-31. 2004
    ..These genes provide a basis for further studies of metastatic progression and local invasiveness, and can be evaluated as therapeutic targets...
  15. ncbi request reprint Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Melanoma Res 14:207-10. 2004
    ..Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence...
  16. pmc The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA
    J Transl Med 5:6. 2007
    ..Targeting XIAP warrants additional investigation as a therapeutic approach for metastatic melanoma...
  17. pmc A phase 2 trial of dasatinib in advanced melanoma
    Harriet M Kluger
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Cancer 117:2202-8. 2011
    ..Dasatinib inhibits c-kit, PDGFβR, and EPHA2 and src kinases c-src, c-Yes, Lck, and Fyn. A phase 2 trial of dasatinib in melanoma was conducted to assess response rate (RR), progression-free survival (PFS), and toxicity...
  18. ncbi request reprint Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis
    Harriet M Kluger
    Departments of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 10:173-7. 2004
    ..Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data...
  19. ncbi request reprint Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
    Keith Hoek
    Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520 8059, USA
    Cancer Res 64:5270-82. 2004
    ..These results provide a comprehensive view of changes in advanced melanoma relative to normal melanocytes and reveal new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients...
  20. pmc Integrated analysis of tumor samples sheds light on tumor heterogeneity
    Fabio Parisi
    Department of Pathology and Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA
    Yale J Biol Med 85:347-61. 2012
    ..These findings show that the integrated approaches used in the present study can robustly address the challenging issue of tumor heterogeneity in high-throughput profiling...
  21. pmc Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    Mod Pathol 21:1121-9. 2008
    ..80 for distinguishing benign nevi from malignant melanomas. On the basis of this preliminary study, we propose that the ratio of nuclear to non-nuclear HMB45 staining may be useful for diagnostic challenges in melanocytic lesions...
  22. ncbi request reprint Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease
    Harriet M Kluger
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Res 65:5578-87. 2005
    ....
  23. pmc Melanoma prognostic model using tissue microarrays and genetic algorithms
    Bonnie E Gould Rothberg
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 27:5772-80. 2009
    ..Here, we propose a multimarker molecular prognostic assay that can help triage patients at increased risk of recurrence...
  24. ncbi request reprint Ipilimumab-induced perforating colitis
    Kisha A Mitchell
    Department of Pathology, Yale University School of Medicine Department of Internal Medicine Medical Oncology, Yale Cancer Center, New Haven, CT Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
    J Clin Gastroenterol 47:781-5. 2013
    ..In the setting of progressive or worsening diarrhea after steroid therapy in patients with colitis, bowel perforation should be considered. ..
  25. ncbi request reprint Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome
    Aaron J Berger
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 64:8767-72. 2004
    ....
  26. ncbi request reprint High HSP90 expression is associated with decreased survival in breast cancer
    Elah Pick
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer Res 67:2932-7. 2007
    ..Prospective studies are needed to confirm the prognostic role of HSP90, as well as the predictive role of HSP90 expression in patients treated with HSP90 inhibitors...
  27. ncbi request reprint Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer
    Nicolas Acquavella
    Melanoma Program, Yale Cancer Center, Yale New Haven Hospital, 333 Cedar Street, New Haven, CT 06520, USA
    J Immunother 31:569-76. 2008
    ..In summary, the twice-daily IL-2 regimen has meaningful activity, may be more convenient to administer, reduces the need for elective monitored beds, and may be preferable for development of combinations with newer immune modulators...
  28. doi request reprint Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer
    Yasmine Nadler
    Department of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 14:4455-62. 2008
    ..We therefore assessed expression of Aurora A and B in breast tumors and studied associations with clinical/pathologic variables...
  29. doi request reprint Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib
    Lucia Jilaveanu
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 15:1076-85. 2009
    ..We assessed the expression of sorafenib targets in SCP-treated patient specimens and evaluated the association with response and progression-free survival...
  30. doi request reprint Chemotherapy and biologic therapies for melanoma: do they work?
    Lucia B Jilaveanu
    Department of Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Clin Dermatol 27:614-25. 2009
    ..This contribution summarizes the risks and benefits of older regimens and discusses the newer, targeted therapies...
  31. ncbi request reprint Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer
    Mary M McCarthy
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 11:5188-94. 2005
    ..We sought to determine the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in early-stage breast cancer...
  32. pmc Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma
    Mary M McCarthy
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 12:3856-63. 2006
    ..We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi...
  33. pmc C-Raf is associated with disease progression and cell proliferation in a subset of melanomas
    Lucia B Jilaveanu
    Yale Cancer Center and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 15:5704-13. 2009
    ..Although the role of B-Raf in melanoma is well established, little is known about C-Raf. We studied effects of C-Raf knockdown in vitro and assessed expression of C-Raf in a large cohort of melanomas and nevi...
  34. ncbi request reprint Assessing expression of apoptotic markers using large cohort tissue microarrays
    Elah Pick
    Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
    Methods Mol Biol 414:83-93. 2008
    ....
  35. ncbi request reprint Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer
    Malini Harigopal
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 11:4083-9. 2005
    ..We investigated the relationship between E-cadherin expression in primary invasive ductal tumors and corresponding nodal metastases, and determined the prognostic value of E-cadherin expression in node-positive breast cancer...
  36. doi request reprint Phosphatidylinositol-3-kinase as a therapeutic target in melanoma
    Saadia A Aziz
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Cancer Res 15:3029-36. 2009
    ..We assessed expression of PI3K in melanomas and nevi, and studied associations between PI3K pathway members and in vitro response to a PI3K inhibitor, LY294002...
  37. pmc Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays
    Janice M Mehnert
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Hum Pathol 41:375-84. 2010
    ..Such assessments could assist with evaluation of these molecules as therapeutic targets in melanoma, ultimately facilitating improved selection of patients for treatment...
  38. pmc Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer
    Kenneth D Bromberg
    Signal Transduction Program, The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
    Cancer Res 67:8172-9. 2007
    ....
  39. ncbi request reprint alphaB-crystallin as a marker of lymph node involvement in breast carcinoma
    Dina Chelouche-Lev
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2543-8. 2004
    ..The objective of the current study was to determine whether the expression of alphaB-crystallin in primary breast carcinomas was associated with lymph node metastasis and survival...

Research Grants4

  1. Predicting Melanoma Response to BAY 43-9006/Chemotherapy
    Harriet Kluger; Fiscal Year: 2005
    ..We will assess individual markers as well as panels of markers. ..
  2. Predicting Melanoma Response to BAY 43-9006/Chemotherapy
    Harriet Kluger; Fiscal Year: 2006
    ..We will assess individual markers as well as panels of markers. ..
  3. Predicting Melanoma Response to BAY 43-9006/Chemotherapy
    Harriet Kluger; Fiscal Year: 2007
    ..We will assess individual markers as well as panels of markers. ..